메뉴 건너뛰기
Cancer Chemotherapy and Pharmacology
Volumn 62, Issue 1, 2008, Pages 181-182
Rapid complete remission in multiple myeloma with bortezomib/thalidomide/ dexamethasone combination therapy following development of tumor lysis syndrome
Author keywords

[No Author keywords available]
Indexed keywords

BORTEZOMIB; DEXAMETHASONE; LACTATE DEHYDROGENASE; M PROTEIN; THALIDOMIDE;
EID: 42149137393     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0574-9     Document Type: Letter
Times cited : (8)
References (7)
  • 1
    • 0037973279 scopus 로고    scopus 로고
    • A phase 2 study of bortezomib in relapsed, refractory myeloma
    • Richardson PG, Barlogie B, Berenson J, et al (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609-2617
    • (2003) N Engl J Med , vol.348 , pp. 2609-2617
    • Richardson, P.G.1    Barlogie, B.2    Berenson, J.3
  • 2
    • 20444433230 scopus 로고    scopus 로고
    • Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
    • Richardson PG, Sonneveld P, Schuster MW, et al (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352:2487-2498
    • (2005) N Engl J Med , vol.352 , pp. 2487-2498
    • Richardson, P.G.1    Sonneveld, P.2    Schuster, M.W.3
  • 3
    • 33748287079 scopus 로고    scopus 로고
    • Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: Results of a multicenter phase 1/2 study
    • Mateos M-V, Hernandez J-M, Hernandez M-T, et al (2006) Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood 108:2165-2172
    • (2006) Blood , vol.108 , pp. 2165-2172
    • Mateos, M.-V.1    Hernandez, J.-M.2    Hernandez, M.-T.3
  • 4
    • 0036512435 scopus 로고    scopus 로고
    • Multiple myeloma: Evolving genetic events and host interactions
    • Kuehl WM, Bergsagel PL (2002) Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer. 2:175-187
    • (2002) Nat Rev Cancer. , vol.2 , pp. 175-187
    • Kuehl, W.M.1    Bergsagel, P.L.2
  • 5
    • 5644266386 scopus 로고    scopus 로고
    • Tumour lysis syndrome in multiple myeloma after bortezomib (VELCADE) administration
    • Terpos E, Politou M, Rahemtulla A (2004) Tumour lysis syndrome in multiple myeloma after bortezomib (VELCADE) administration. J Cancer Res Clin Oncol 130:623-625
    • (2004) J Cancer Res Clin Oncol , vol.130 , pp. 623-625
    • Terpos, E.1    Politou, M.2    Rahemtulla, A.3
  • 6
    • 33746700799 scopus 로고    scopus 로고
    • Tumor lysis syndrome early after treatment with bortezomib for multiple myeloma
    • Kenealy MK, Prince HM, Honemann D (2006) Tumor lysis syndrome early after treatment with bortezomib for multiple myeloma. Pharmacotherapy 26:1205-1206
    • (2006) Pharmacotherapy , vol.26 , pp. 1205-1206
    • Kenealy, M.K.1    Prince, H.M.2    Honemann, D.3
  • 7
    • 1842579486 scopus 로고    scopus 로고
    • Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis
    • 8
    • Bharti AC, Shishodia S, Reuben JM, Weber D, Alexanian R, Raj-Vadhan S, Estrov Z, Talpaz M, Aggarwal BB (2004) Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood 103(8):3175-3184
    • (2004) Blood , vol.103 , pp. 3175-3184
    • Bharti, A.C.1    Shishodia, S.2    Reuben, J.M.3    Weber, D.4    Alexanian, R.5    Raj-Vadhan, S.6    Estrov, Z.7    Talpaz, M.8    Aggarwal, B.B.9

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.